Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy of Denosumab 60mg sc Every 3 Months in Patients With Erosive Osteoarthritis of the Interphalangeal Finger Joints
Phase of Trial: Phase II
Latest Information Update: 10 Nov 2017
At a glance
- Drugs Denosumab (Primary)
- Indications Osteoarthritis
- Focus Proof of concept; Therapeutic Use
- 06 Nov 2017 Planned End Date changed from 1 Sep 2019 to 1 Jan 2019.
- 06 Nov 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Sep 2018.
- 17 May 2016 New trial record